Summary
Background. The prognosis of glioblastoma multiforme remains poor despite recent therapeutic advances. Several clinical and therapeutic factors as well as tumour characteristics have been reported as significant to survival. A more efficient determination of the prognostic factors is required to optimize individual therapeutic management. The aim of our study was to evaluate by univariate then multivariate analysis the factors that influence prognosis and particularly survival.
Methods. Data of 340 patients with newly-diagnosed GBM were retrospectively analyzed. Univariate analysis of prognosis factors of survival time was performed. Factors that seemed determinant were evaluated by Kaplan–Meier survival curves. Finally, the significant factors found in univariate analysis were tested in multivariate analysis using the COX regression method.
Findings. Using multivariate analysis, the following factors were found to influence survival: radiotherapy was the predominant factor followed by radical surgery, tumour location, age and chemotherapy. Patients treated with temozolomide had a markedly better survival rate than patients treated with other chemotherapies (Log-rank test P < 0.005). The values of GBM type (de novo or secondary), as well as repeated surgery and partial surgery (vs. simple biopsy) were suggested by univariate analysis but not confirmed by the COX regression method. After radical surgery, progression-free survival was correlated to overall survival (r = 0.87, P < 10e-5).
Conclusions. The influence of radiotherapy on survival was greater than the influence of age, an argument supporting the proposition of radiotherapy for patients until at least age 70. In the case of recurrence, the correlation between overall survival and progression-free survival is an important factor when considering the therapeutic options. Initial radical surgery and repeated procedures dramatically influence survival. The benefit of partial surgery remains difficult to evaluate. Partial surgery could be used to decrease intracranial pressure and to minimize residual tumours in order to enable treatment by chemotherapy and radiotherapy. The value of temozolomide treatment was confirmed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
FK Albert M Forsting K Sartor HP Adams S Kunse (1994) ArticleTitleEarly postoperative magnetic resonance imaging after resection of malignant glioma: objective evaluation of residual tumor and its influence on regrowth and prognosis Neurosurgery 34 IssueID1 45–61 Occurrence Handle8121569 Occurrence Handle10.1097/00006123-199401000-00008 Occurrence Handle1:STN:280:DyaK2c7ms12ksg%3D%3D
M Bussiere W Hopman A Day AP Pombo T Neves F Espinosa (2005) ArticleTitleIndicators of functional status for primary malignant brain tumor patients Can J Neurol Sci 32 IssueID1 50–56 Occurrence Handle15825546
DR Cox (1972) ArticleTitleRegression models and life tables J R Stat Soc B 34 187–220
C Daumas-Duport B Scheithauer J O’Fallon P Kelly (1988) ArticleTitleGrading of astrocytomas. A simple and reproducible method Cancer 62 IssueID10 2152–2165 Occurrence Handle3179928 Occurrence Handle10.1002/1097-0142(19881115)62:10<2152::AID-CNCR2820621015>3.0.CO;2-T Occurrence Handle1:STN:280:DyaL1M%2FivVSqtg%3D%3D
BC Devaux JR O’Fallon PJ Kelly (1993) ArticleTitleResection, biopsy and survival in malignant glial neoplasms. A retrospective study of clinical parameters, therapy, and outcome J Neurosurg 78 IssueID5 767–775 Occurrence Handle8468607 Occurrence Handle1:STN:280:DyaK3s3isV2ktw%3D%3D
H Fujisawa RM Reis M Nakamura S Colella Y Yonekawa P Kleihues H Ohgaki (2000) ArticleTitleLoss of heterozygosity on chromosome 10 is more extensive in primary (de novo) than in secondary glioblastomas Lab Invest 80 IssueID1 65–71 Occurrence Handle10653004 Occurrence Handle1:CAS:528:DC%2BD3cXhtVeqs7w%3D Occurrence Handle10.1038/labinvest.3780009
ME Hegi AC Diserens T Gorlia MF Hamou N De Tribolet M Weller JM Kros JA Hainfeller W Mason L Mariani JE Bromberg P Hau RO Mirimanoff JG Cairncross RC Janser R Stupp (2005) ArticleTitleMGMT gene silencing and benefit from temozolomide in glioblastoma N Engl J Med 352 IssueID10 997–1003 Occurrence Handle15758010 Occurrence Handle10.1056/NEJMoa043331 Occurrence Handle1:CAS:528:DC%2BD2MXit1Wktro%3D
EM Hiesiger RL Hayes DM Pierz GN Budzilovich (1993) ArticleTitlePrognostic relevance of epidermal growth factor receptor (EGF-R) and c-neu/erbB2 expression in glioblastomas J Neurooncol 16 IssueID2 93–104 Occurrence Handle7507162 Occurrence Handle10.1007/BF01324695 Occurrence Handle1:STN:280:DyaK2c7hvVSktw%3D%3D
EL Kaplan P Meier (1958) ArticleTitleNon parametric estimation from incomplete observations J Am Stat Assoc 53 457–481 Occurrence Handle10.2307/2281868
GE Keles B Anderson MS Berger (1999) ArticleTitleThe effect of extent of resection on time to tumor progression and survival in patients with glioblastoma multiforme of the cerebral hemisphere Surg Neurol 52 IssueID4 371–379 Occurrence Handle10555843 Occurrence Handle10.1016/S0090-3019(99)00103-2 Occurrence Handle1:STN:280:DC%2BD3c%2Fit1Oluw%3D%3D
P Kleihues WK Cavenee (2000) Pathology and genetic of tumors of the nervous system: World Health Organization Classification of tumors NumberInSeries1 IARC Press Lyon, France 55–69
P Kleihues H Ohgaki (1999) ArticleTitlePrimary and secondary glioblastomas: from concept to clinical diagnosis Neuro-Oncology 1 44–51 Occurrence Handle11550301 Occurrence Handle10.1215/15228517-1-1-44 Occurrence Handle1:STN:280:DC%2BD3MrgtFCktg%3D%3D
M Lacroix D Abi-Said DR Fourney ZL Gokaslan W Shi F Demonte FF Lang IE McCutcheon SJ Hassenbusch E Holland K Hess C Michael D Miller R Sawaya (2001) ArticleTitleA multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extend of resection of resection and survival J Neurosurg 95 IssueID2 190–198 Occurrence Handle11780887 Occurrence Handle1:STN:280:DC%2BD38%2FlsFGitA%3D%3D
FF Lang DC Miller M Koslow EW Newcomb (1994) ArticleTitlePathways leading to glioblastoma multiforme: a molecular analysis of genetic alterations in 65 astrocytic tumors J Neurosurg 81 IssueID3 427–436 Occurrence Handle8057151 Occurrence Handle1:STN:280:DyaK2czjsVOgsg%3D%3D
A Mangiola G Maira P De Bonis P Porso B Pettorini G Sabatino C Anile (2006) ArticleTitleGlioblastoma multiforme in the elderly: a therapeutic challenge J Neurooncol 76 IssueID2 159–163 Occurrence Handle16132492 Occurrence Handle10.1007/s11060-005-4711-1 Occurrence Handle1:STN:280:DC%2BD28%2Fitlaguw%3D%3D
JF Mineo I Quintin-Roue B Lucas V Buburuzan G Besson (2002) ArticleTitleGlioblastomas: clinical study and prognosis factors Neurochirurgie 48 IssueID6 500–509 Occurrence Handle12595806
JF Mineo A Bordron I Quintin-Roué S Loisel K Le Ster V Buhé N Lagarde C Berthou (2004) ArticleTitleRecombinant Humanized Anti-HER2/neu Antibody (Herceptin®) induces cellular death of glioblastomas Br J Cancer 91 IssueID6 1195–1199 Occurrence Handle15328518 Occurrence Handle1:CAS:528:DC%2BD2cXot1Cksbs%3D
M Nozaki M Tada H Kobayashi CL Zhang Y Sawamura H Abe N Ishii EG Van Meir (1999) ArticleTitleRoles of the functional loss of P53 and other genes in astrocytoma tumorigenesis and progression Neuro-Oncology 1 IssueID2 124–137 Occurrence Handle11550308 Occurrence Handle1:STN:280:DC%2BD3MrgtFCrsw%3D%3D
A Obwegeser M Ortler M Seiwald H Ulmer H Kostron (1995) ArticleTitleTherapy of glioblastoma multiforme: a cumulative experience of 10 years Acta Neurochir (Wien) 137 IssueID1 29–33 Occurrence Handle10.1007/BF02188776 Occurrence Handle1:STN:280:DyaK28zltVKhsA%3D%3D
H Ohgaki P Kleihues (2005) ArticleTitleEpidemiology and etiology of gliomas Acta Neuropathol 109 IssueID1 93–108 Occurrence Handle15685439 Occurrence Handle10.1007/s00401-005-0991-y
RS Polin NF Marko MD Ammerman ME Shaffrey W Huang FA Anderson SuffixJr AJ Caputy ER Laws (2005) ArticleTitleFunctional outcomes and survival in patients with high-grade gliomas in dominant and nondominant hemispheres J Neurosurg 102 IssueID2 276–283 Occurrence Handle15739555
F Puzzilli A Ruggeri L Mastronardi D Di Stephano P Lunardi (1998) ArticleTitleLong-term survival in cerebral glioblastoma. Case report and critical review of the literature Tumori 84 IssueID1 69–74 Occurrence Handle9619719 Occurrence Handle1:STN:280:DyaK1c3otFSiug%3D%3D
NG Rainov KU Dobberstein H Bahn HJ Holzhausen C Lautenschlager V Heideke W Burkert (1997) ArticleTitlePrognosis factors in malignant glioma: Influence of the overexpression of oncogene and tumor-suppressor gene products on survival J Neurooncol 35 IssueID1 13–28 Occurrence Handle9266437 Occurrence Handle10.1023/A:1005841520514 Occurrence Handle1:STN:280:DyaK2svhtFCmuw%3D%3D
J Shinoda N Sakai S Murase H Yano T Matsuhisa T Funakoshi (2001) ArticleTitleSelection of eligible patients with supratentorial glioblastoma gross total resection J Neurooncol 52 IssueID2 161–171 Occurrence Handle11508816 Occurrence Handle10.1023/A:1010624504311 Occurrence Handle1:STN:280:DC%2BD3MvmtlKrtw%3D%3D
DC Shrieve E Alexander PM Black PY Wen HA Fine HM Kooy JS Loeffler (1999) ArticleTitleTreatment of patient with primary glioblastoma multiforme with standart postoperative radiotherapy and radiosurgical boost: prognostic factors and long-term outcome J Neurosurg 90 IssueID1 72–77 Occurrence Handle10413158 Occurrence Handle1:STN:280:DyaK1MzjvFGjsQ%3D%3D
DL Silbergeld RC Rostomily EC Alvord SuffixJr (1991) ArticleTitleThe cause of death in patients with glioblastoma is multifactorial: clinical factors and autopsy findings in 117 cases of supratentorial glioblastoma in adults J Neurooncol 10 IssueID2 179–185 Occurrence Handle1654403 Occurrence Handle10.1007/BF00146880 Occurrence Handle1:STN:280:DyaK3MznsVWquw%3D%3D
AM Stark A Nabavi HM Mehdorn U Blömer (2005) ArticleTitleGlioblastoma multiforme: report of 267 cases treated at a single institution Surg Neurol 63 IssueID2 162–169 Occurrence Handle15680662 Occurrence Handle10.1016/j.surneu.2004.01.028
W Stummer A Novotny H Stepp C Goetz K Bize HJ Reulen (2000) ArticleTitleFluorescence-guided resection of glioblastoma multiforme by using 5-aminolevulinic acid induced porphyrins: a prospective study of 52 consecutive patients J Neurosurg 93 IssueID6 1003–1013 Occurrence Handle11117842 Occurrence Handle1:CAS:528:DC%2BD3cXptValsro%3D Occurrence Handle10.3171/jns.2000.93.6.1003
R Stupp WP Mason MJ van den Bent M Weller B Fisher MJ Taphoorn K Belanger AA Brandes C Marosi U Bogdahn J Curshmann RC Janzer SK Ludwin T Gorlia A Allgeier D Lacombe JG Cairncross E Eisenhauer RO Mirimanoff (2005) ArticleTitleRadiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 IssueID10 987–996 Occurrence Handle15758009 Occurrence Handle10.1056/NEJMoa043330 Occurrence Handle1:CAS:528:DC%2BD2MXit1Wksbk%3D
Y Tohma C Gratas W Biernat A Peraud M Fukuda Y Yonekawa P Kleihues H Ohgaki (1998) ArticleTitlePTEN (MMAC1) Mutation are frequent in primary glioblastomas but not in secondary glioblastomas J Neuropathol Exp Neurol 57 IssueID7 684–689 Occurrence Handle9690672 Occurrence Handle1:CAS:528:DyaK1cXlt1alsL0%3D
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mineo, JF., Bordron, A., Baroncini, M. et al. Prognosis factors of survival time in patients with glioblastoma multiforme: a multivariate analysis of 340 patients. Acta Neurochir (Wien) 149, 245–253 (2007). https://doi.org/10.1007/s00701-006-1092-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00701-006-1092-y